(1 - 22 von 23
)
FDA approves cystic fibrosis treatment - UPI Archives
www.upi.com
U.S. and Canadian health authorities Thursday approved a genetically engineered drug that relieves the persistent lung congestion in cystic fibrosis...
Genomic Health's Steven Shak targets diagnostic cancer ...The Business Journals
www.bizjournals.com
— Dr. Steven Shak is co-founder of Genomic Health in Redwood City. There, he has two positions in the C-Suite: chief medical officer and chief ...
Many women with early-stage breast cancer can skip ...Reuters
www.reuters.com
— Steven Shak, chief scientific officer at Genomic Health, said about four in 10 women in the United States with early stage breast cancers are ...
Steven Shak with Gail Shak
drewaltizer.com
Steven Shak and Gail Shak attend American Cancer Society's Discovery Gala on September 17th in San Francisco, CA
People in the News: Joffre Baker, Steven Shak, Felix BakerGenomeWeb
www.genomeweb.com
— Steven Shak, chief medical officer, has assumed responsibility for managing the research operations, which were formerly handled by Baker.
Genomic reports positive results from two feasibility trials of...
www.medicaldevice-network.com
US-based Genomic Health has reported positive results from its first two feasibility trials evaluating multiple technologies.
NICE empfiehlt Oncotype DX® Test - Krebs-Nachrichten
www.krebs-nachrichten.de
... sagte Dr. Steven Shak, Executive Vice President für Forschung und Entwicklung bei Genomic Health. „Die umfassende klinische Evidenz ermöglicht dem Test, ...
Implementing a National Cancer Clinical Trials System for ...National Academies
www.nationalacademies.org
Implementing a National Cancer Clinical. Trials System for the 21st Century. Diagnostics Industry Perspective. Steven Shak, MD. Chief Medical Officer.
Breast Cancer, Research, Treatment, Patient Support
www.cancercare.org
Dr. Steven Shak, Genomic Health's founder and chief medical officer, accepted CancerCare's Beacon Award, in recognition of Genomics' ...
Customizing cancer care - Los Angeles Times
www.latimes.com
A new screening could predict the aggressiveness of a patient's disease and lead to more personalized, and effective, treatment.
PHOTOS: SCENES FROM OUR C-SUITE AWARDS ...YMCA Silicon Valley
www.ymcasv.org
... Mark Papermaster, chief technology officer, AMD; C-Suite Other, Public Company, Steven Shak, M.D., chief medical officer and chief scientific officer, ...
Genentech: Passion Project
www.gene.com
A new hire pursues an idea, from musty journals to clinical trials, eventually changing the way cystic fibrosis is treated.
Faculty Publications: July 28-August 4Cedars-Sinai
www.cedars-sinai.org
— King, Steven Shak, Christy A. Russell, Armando E. Giuliano, Gabriel N. Hortobagyi, Eric P. Winer, Larissa A. Korde, Joseph A. Sparano, and ...
Passion ProjectGenentech
www.gene.com
— A pulmonologist by training, Steven Shak, M.D., frequently found his thoughts turning to lung disease. That day, he recalled the kids with ...
Police Reports: July 30, 2022Marshall News Messenger
www.marshallnewsmessenger.com
— Steven Shak Ingram, 44, of Henderson was arrested and charged with Gregg County warrants for theft of property worth less than $2,500 with ...
Close Biotechgate Biotechgate | | Twitter LinkedIn Google+ ...
www.maltesebiotech.com
... evidence generated by independent researchers and Genomic Health is paramount, highlighting the accuracy of Oncotype DX in predicting clinical outcomes and its unique value in providing physicians with critical genomic intelligence to enhance breast cancer treatment decisions and patient benefit," said Steven Shak, ...
Close Biotechgate Biotechgate | | Twitter LinkedIn Google+ ...
www.romanianbiotech.com
... hormonal therapy alone," said Steven Shak, M.D., chief scientific officer, Genomic Health. "Collectively with the TAILORx trial results in the low-risk cohort, the new data presented at ECC2015 provide the highest level of clinical evidence demonstrating the practice-changing impact of the Oncotype DX test ...
Stockwatch
www.stockwatch.com
No Hype - just the Facts. Your complete source of news and realtime quotes from the TSX, TSX-V, CSE, Montreal, Nasdaq, NYSE, Amex and OTC Markets.
Genomic Health and Almac Group Enter Exclusive In-Licensing Agreement...
www.almacgroup.com
“Working with Almac, we have the opportunity to gain further insight on the role of DNA repair in drug efficacy, which may provide clinical utility to help select which breast cancer patients benefit from specific chemotherapy drugs and regimens,” said Steven Shak, M.D., Executive Vice President of Research ...
New data demonstrate that Oncotype DX® can help guide treatment...
www.prnewswire.co.uk
GENEVA, Dec. 12, PR Newswire UK/ -- New data demonstrate that Oncotype DX® can help guide treatment decisions before breast cancer surgery enabling...
TAILORx trial finds 99% of women with low Oncotype DX® Recurrence...
www.newswire.ca
TORONTO, Sept. 28, TAILORx trial finds 99% of women with low Oncotype DX® Recurrence Score® are free of breast cancer recurrence after five years of...
Unnecessary chemotherapy for breast cancer may be reduced – The...
www.irishtimes.com
Patients can be genetically tested tested to see who would benefit from the treatment
sortiert nach Relevanz / Datum